Targeting carcinogen-regulated immune factors like M-CSF/CSF1R in combination with ICB therapy highlight promising therapeutic strategies that can be uncovered by exploring the TMB/neoantigen-independent immunological impacts of environmental carcinogens on cancer development. Here, CSF1R is linked to cancer.